171 related articles for article (PubMed ID: 10914920)
1. Reduction of background activity through radiolabeling of antifibrin Fab' with 99mTc-dextran.
Line BR; Weber PB; Lukasiewicz R; Dansereau RN
J Nucl Med; 2000 Jul; 41(7):1264-70. PubMed ID: 10914920
[TBL] [Abstract][Full Text] [Related]
2. Tc-99m antifibrin Fab' fragments for imaging venous thrombi: evaluation in a canine model.
Knight LC; Maurer AH; Ammar IA; Epps LA; Dean RT; Pak KY; Berger HJ
Radiology; 1989 Oct; 173(1):163-9. PubMed ID: 2781002
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab'.
Macfarlane DJ; Smart RC; Tsui WW; Gerometta M; Eisenberg PR; Scott AM
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):648-56. PubMed ID: 16528525
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive detection of atherosclerotic lesions by 99mTc-based immunoscintigraphic targeting of proliferating smooth muscle cells.
Narula J; Petrov A; Pak KY; Ditlow C; Chen F; Khaw BA
Chest; 1997 Jun; 111(6):1684-90. PubMed ID: 9187194
[TBL] [Abstract][Full Text] [Related]
5. Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab' fragment (99mTc-DI-DD3B6/22-80B3): results of a phase I trial.
Macfarlane D; Socrates A; Eisenberg P; Larcos G; Roach P; Gerometta M; Smart R; Tsui W; Scott AM
Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):250-9. PubMed ID: 18800218
[TBL] [Abstract][Full Text] [Related]
6. Technetium-99 m labelling of DD-3B6/22 antifibrin monoclonal antibody fragment Fab' for thrombus imaging.
Lee FT; Boniface GR; Lambrecht RM; Rylatt DB; Bundesen PG
Immunol Cell Biol; 1993 Apr; 71 ( Pt 2)():117-24. PubMed ID: 8486395
[TBL] [Abstract][Full Text] [Related]
7. Premortem biodistribution of radioactivity in the rat: measurement of blood and tissue activity of tracers used in clinical imaging studies.
Line BR; Herrmannsdoerfer AJ; Battles AH; Weber PB; Dansereau RN; Blumenstock FA
Lab Anim Sci; 1994 Oct; 44(5):495-502. PubMed ID: 7844960
[TBL] [Abstract][Full Text] [Related]
8. The in vivo and in vitro metabolic profile of 99mTc-NC100668, a new tracer for imaging venous thromboembolism: identification and biodistribution of the principal radiolabeled metabolite.
Edwards D; Battle M; Lear R; Farrar G; Barnett DJ; Godden V; Coombes C; Oliveira A; Ahlström H
Drug Metab Dispos; 2006 Jul; 34(7):1128-35. PubMed ID: 16611856
[TBL] [Abstract][Full Text] [Related]
9. A synthetic macromolecule for sentinel node detection: (99m)Tc-DTPA-mannosyl-dextran.
Vera DR; Wallace AM; Hoh CK; Mattrey RF
J Nucl Med; 2001 Jun; 42(6):951-9. PubMed ID: 11390562
[TBL] [Abstract][Full Text] [Related]
10. Dextran-conjugated vascular endothelial growth factor receptor antibody for in vivo melanoma xenografted mouse imaging.
Kim EM; Jeong HJ; Jeong MH; Lee CM; Cheong SJ; Kim DW; Lim ST; Sohn MH
Cancer Biother Radiopharm; 2012 Mar; 27(2):141-8. PubMed ID: 22149589
[TBL] [Abstract][Full Text] [Related]
11. Studying the biological feasibility of [⁹⁹mTc(CO)₃]-dextran-cysteine-cysteine-mannose as a potential molecular radiopharmaceutical for sentinel node detection.
Khan IU; Shahid A; Ahmad F; Dar UK; Ahmad M; Javed M
Ann Nucl Med; 2014 Apr; 28(3):248-56. PubMed ID: 24390658
[TBL] [Abstract][Full Text] [Related]
12. Cardiopulmonary thromboembolism detected by Tc-99m MH-1 antifibrin antibody.
Line BR; Keenan JF; Lukasiewicz RL; Dansereau RN; Tublin ME; Williams LM; Gargan PE
Clin Nucl Med; 1997 Jun; 22(6):376-9. PubMed ID: 9193807
[TBL] [Abstract][Full Text] [Related]
13. Design and development of (99m)tc-'4+1'-labeled dextran-mannose derivatives as potential radiopharmaceuticals for sentinel lymph node detection.
Giglio J; Fernández S; Jentschel C; Pietzsch HJ; Papadopoulos M; Pelecanou M; Pirmettis I; Paolino A; Rey A
Cancer Biother Radiopharm; 2013 Sep; 28(7):541-51. PubMed ID: 23651043
[TBL] [Abstract][Full Text] [Related]
14. Studies toward the biological efficacy of (99m)Tc-labeled dextran-cysteine-mannose ([(99m)Tc(CO)(3)]DCM20) for sentinel lymph node detection.
Subramanian S; Pandey U; Papadopoulos M; Pirmettis I; Venkatesh M; Samuel G
Cancer Biother Radiopharm; 2012 Aug; 27(6):365-70. PubMed ID: 22690877
[TBL] [Abstract][Full Text] [Related]
15. A comparison of cleavable and noncleavable hydrazinopyridine linkers for the 99mTc labeling of Fab' monoclonal antibody fragments.
Bridger GJ; Abrams MJ; Padmanabhan S; Gaul F; Larsen S; Henson GW; Schwartz DA; Longley CB; Burton CA; Ultee ME
Bioconjug Chem; 1996; 7(2):255-64. PubMed ID: 8983348
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of accumulation of 99mTc-sulesomab in inflammation.
Skehan SJ; White JF; Evans JW; Parry-Jones DR; Solanki CK; Ballinger JR; Chilvers ER; Peters AM
J Nucl Med; 2003 Jan; 44(1):11-8. PubMed ID: 12515870
[TBL] [Abstract][Full Text] [Related]
17. Imaging arterial thrombosis: comparison of technetium-99m-labeled monoclonal antifibrin antibodies and indium-111-platelets.
Stratton JR; Cerqueira MD; Dewhurst TA; Kohler TR
J Nucl Med; 1994 Nov; 35(11):1731-7. PubMed ID: 7965148
[TBL] [Abstract][Full Text] [Related]
18. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
[TBL] [Abstract][Full Text] [Related]
19.
Rashed HM; Marzook FA; Farag H
Radiol Med; 2016 Dec; 121(12):935-943. PubMed ID: 27586132
[TBL] [Abstract][Full Text] [Related]
20. The rabbit biodistribution of a therapeutic dose of zoledronic acid labeled with Tc-99m.
Asikoglu M; Durak FG
Appl Radiat Isot; 2009 Sep; 67(9):1616-21. PubMed ID: 19457677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
